FDA Grants Priority Review to Pembrolizumab Monotherapy for TMB-High Tumors

The FDA granted priority review to pembrolizumab monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic TMB-high solid tumors who have progressed following prior treatment and who have no satisfactory alternative treatment options.

Planned Phase III Trial of Ruxolitinib Plus Standard-of-Care for Patients with COVID-19

Incyte announced that they are working with the FDA to initiate a phase III clinical trial to assess ruxolitinib (Jakafi) plus standard-of-care in patients with coronavirus disease 2019 (COVID-19) induced cytokine storm.

Artificial Intelligence Could Help Predict Tumor Sensitivity for Patients with NSCLC

Researchers determined that artificial intelligence could help predict responses to systemic therapies for patients with non-small cell lung cancer by utilizing CT scans.